Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.

about

Beta-blockers in patients with advanced liver disease: Has the dust settled?Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.Management of refractory cirrhotic ascites: challenges and solutions

P2860

Q38673738-4936F3D1-4FCF-4E12-88B6-C4FAB565DADD Q42261445-4D783800-1C2F-49E6-82A8-39D32007A35C Q57407557-A009281B-34F8-4D1F-94D7-3FB1B0DD8501

P2860

Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.

Item

http://www.wikidata.org/entity/Q48122792

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Non-selective beta-blockers ar ...... rrhotic patients with ascites.

@en

Non-selective beta-blockers ar ...... rrhotic patients with ascites.

@nl

type

Item

label

Non-selective beta-blockers ar ...... rrhotic patients with ascites.

@en

Non-selective beta-blockers ar ...... rrhotic patients with ascites.

@nl

prefLabel

Non-selective beta-blockers ar ...... rrhotic patients with ascites.

@en

Non-selective beta-blockers ar ...... rrhotic patients with ascites.

@nl

P1476

Non-selective beta-blockers ar ...... irrhotic patients with ascites

@en

P2093

David Patch

http://www.w3.org/2001/XMLSchema#string

Gioacchino Leandro

http://www.w3.org/2001/XMLSchema#string

Maria Kalafateli

http://www.w3.org/2001/XMLSchema#string

Rachel Westbrook

http://www.w3.org/2001/XMLSchema#string

P2860

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multic

U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.

EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

New therapeutic paradigm for patients with cirrhosis.

Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.

Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.

Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.

Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.

Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites.

P304

1334-1344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.13409

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28296047

http://www.w3.org/2001/XMLSchema#string

Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.

about

P2860

P2860

Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698